Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer

• Main Authors: Esse I. H. Akpo (Author), Irshaad R. Jansen (Author), Edith Maes (Author), Steven Simoens (Author)
• Formato: Livro
• Publicado em: Frontiers Media S.A., 2017-09-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Background: Lipegfilgrastim (Lonquex®) has demonstrated to be non-inferior to pegfilgrastim (Neulasta®) in reducing the duration of severe neutropenia (SN) in patients with stage II−IV breast cancer. Compared to pegfilgrastim, lipegfilgrastim also demonstrated statistically significant lower time to...